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BACKGROUND: The nucleoside analog cytarabine
(Ara-C [cytosine arabinoside]) is the key agent for
treating acute myeloid leukemia (AML); however, up
to 30% of patients fail to respond to treatment. Screen-
ing of patient blood samples to determine drug re-
sponse before commencement of treatment is needed.
This project aimed to construct and evaluate a self-
bioluminescent reporter strain of Escherichia coli for
use as an Ara-C biosensor and to design an in vitro
assay to predict Ara-C response in clinical samples.
METHODS: Weused transpositionmutagenesis to create
a cytidine deaminase (cdd)-deficient mutant of E. coli
MG1655 that responded to Ara-C. The strain was
transformed with the luxCDABE operon and used as a
whole-cell biosensor for development an 8-h assay to
determine Ara-C uptake and phosphorylation by leu-
kemic cells.
RESULTS: Intracellular concentrations of 0.025 mol/L
phosphorylated Ara-C were detected by significantly
increased light output (P  0.05) from the bacterial
biosensor. Results using AML cell lines with known
response to Ara-C showed close correlation between
the 8-h assay and a 3-day cytotoxicity test for Ara-C cell
killing. In retrospective tests with 24 clinical samples of
bonemarrow or peripheral blood, the biosensor-based
assay predicted leukemic cell response to Ara-C within
8 h.
CONCLUSIONS: The biosensor-based assay may offer a
predictor for evaluating the sensitivity of leukemic cells
to Ara-C before patients undergo chemotherapy and
allow customized treatment of drug-sensitive patients
with reducedAra-Cdose levels. The 8-h assaymonitors
intracellular Ara-CTP (cytosine arabinoside triphos-
phate) levels and, if fully validated, may be suitable for
use in clinical settings.
© 2010 American Association for Clinical Chemistry
Although cytotoxic chemotherapy is widely used for
treatment of many forms of cancer, failure to respond
to anticancer drugs and resistance to treatment arema-
jor obstacles to satisfactory clinical outcome.Over 30%
of acute myeloid leukemia (AML)8 patients fail to re-
spond to the nucleoside analog cytarabine (Ara-C [cy-
tosine arabinoside]), the main drug used for AML
treatment, and a substantial proportion fail to achieve
long-term remission, whereas others respond to re-
duced levels of the drug (1 ). Currently, patients un-
dergo no prescreening for any of the courses of cyto-
toxic therapy to determine potential response (1 ). For
nonresponding patients, this lack of screening can re-
sult in a delay in commencement of effective treatment
and unnecessary exposure to cytotoxic drugs with as-
sociated morbidity and mortality due to side effects
and potential drug-induced secondary malignancies
(2 ). There is a need for rapid screening of patient sam-
ples to determine level of drug response before com-
mencement of treatment that not only will give in-
creased patient benefits, but also reduce healthcare
costs (1 ). It is anticipated that such a test could be anal-
ogous to the existing antibiotic sensitivity tests rou-
tinely used in clinical settings before antibiotic treat-
ment for infection.
The nucleoside analog Ara-C is one of the most
active single anticancer agents and is the main drug of
chemotherapy for AML (3, 4 ). In vivo, Ara-C is trans-
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ported into the cell via the human equilibrium
nucleoside transporter (hENT1) and is rapidly phos-
phorylated by deoxycytidine kinase (dCK) to itsmono-
phosphate form, cytosine arabinosidemonophosphate
(Ara-CMP), which is further phosphorylated by nucle-
oside kinases and finally to the triphosphorylated and
active form, cytosine arabinoside triphosphate (Ara-
CTP). Drug inactivation can result from Ara-CMP
conversion into Ara-uracil by cytidine deaminase
(cdd), or from dephosphorylation of Ara-CMP by cy-
toplasmic nucleotidase (3 ). The antiproliferative and
cytotoxic effects of Ara-CTP are largely due to its ability
to interfere with DNA polymerase and its incorpora-
tion into DNA strands leading to chain termination
and DNA synthesis arrest (4 ).
Chemoresistance to Ara-C can arise from a number
of factors influencing the rate of Ara-CTP formation and
incorporation into DNA (5), including low drug uptake,
conversion into Ara-uracil by cytidine deaminase, or de-
phosphorylation of active metabolite by cytoplasmic nu-
cleotidase (6). Intracellular concentrations of Ara-CTP
are reported to correlate with response to Ara-C therapy
(4). In vitro assessment of Ara-C efficacy has previously
involved measurement of cell death, assessed by colony
forming units–blast clonogenic assays (7). This method-
ology involves primary cell culture over3 days (7) and
is not suitable for routine screening. In clinical practice,
patients are treated with regimens including Ara-C re-
gardless of their possible nonresponse to the drug and, as
a result, suffer fromdebilitating sideeffects (2, 8). Patients
are given induction therapyover aperiodofweeks, before
sensitivity or resistance is determined by leukemic cell
count (4).
Recombinant cell-based bioluminescence tech-
nology is an approach that has received increasing
attention for biomedical applications (9 ) and has
previously been used for determination of androgen
bioactivity in clinical samples (10). This technology
has the potential to detect anticancer drug activity in
malignant cells from clinical samples, within a period
of hours. Light emission from bioluminescent bacteria
is due to the activity of bacterial luciferase, which cata-
lyzes the oxidation of reduced flavin mononucleotide
(FMNH2) and a long-chain aliphatic aldehyde in the
presence of O2 to produce FMN and acid with the
emission of blue-green light. The genes coding for
the luciferase [alkanal monooxygenase subunit alpha
(luxA)9 and alkanal monooxygenase subunit beta
(luxB)] are linked to those coding for the fatty acid
reductase complex [fatty acid reductase (luxC); acyl
transferase (luxD); and acyl-protein synthetase (long-
chain-fatty-acid-luciferin-component ligase) (luxE)],
which catalyzes the production of luciferin from the
fatty acid pool (11). Because the production of FMNH2
directly depends on a functional electron transport sys-
tem, only metabolically active cells emit light. Hence,
any alteration of cellular metabolism is reflected by a
change in light emission. Bioluminescent bacterial bio-
sensors have been used to assess the effect of various
chemical, biological, and physical signals, providing an
accurate, nondestructive, and real-time assay technol-
ogy (9 ). Bioluminescence phenotype can be conferred
upon most bacteria by introducing and expressing the
luxCDABE operon, isolated from Photorhabdus lumi-
nescens, under the control of constitutive promoters.
These whole-cell bacterial biosensors do not require
exogenous substrate and give out light as a direct indi-
cator of the physiological status of the bacteria in real
time (12). The high metabolic rate of bacterial cells,
compared with mammalian cells, means that these re-
porters are ideal for fast, accurate, real-time in situ tox-
icity testing. Light output from these biosensors can be
accurately measured, with no background interfer-
ence, by using either luminometers or low-light cam-
eras. Lux gene–based reporter technology in bacterial
biosensors has been successfully used tomonitor phar-
macodynamics of antimicrobial agents in real time
(13, 14).
Ara-C has no effect on Escherichia coli, since the
bacteria lack dCK that phosphorylates Ara-C into its
active form and they actively deaminate Ara-C into
Ara-uracil through the activity of cytidine/deoxycyti-
dine deaminase (cdd). Wang et al. (15) constructed a
cdd-deficient E. coli strain (SØ5218) that, upon the ex-
pression of the human deoxycytidine kinase (DCK)
gene, exhibited reduced relative growth in the presence
of Ara-C in minimal growth medium. Therefore, this
indicates that expression of human dCK in SØ5218
leads to the incorporation of Ara-CTP into bacterial
DNA. However, the growth inhibitory effect of Ara-C
was completely abolished when assayed in rich growth
medium due to incorporation of cytosine triphosphate
instead of the toxic analogAra-CTP into bacterialDNA
(15).
Themain aim of this study was the construction of a
pyrimidine-requiring, cdd-deficient mutant of E. coli
MG1655strainwithenhancedsensitivity towardAra-C in
richmedium and its use as a bioluminescent biosensor in
an8-hassay todetermineAra-Cuptakeaswell as itsphos-
phorylation by human leukemic cells. The assay provides
informationon thephenotypeof leukemic cells in clinical
samples of peripheral blood or bonemarrow.
9 Genes: luxA, alkanal monooxygenase subunit alpha; luxB, alkanal monooxy-
genase subunit beta; luxC, fatty acid reductase; luxD, acyl transferase; luxE,
acyl-protein synthetase (long-chain-fatty-acid-luciferin-component ligase); cdd,
cytidine/deoxycytidine deaminase; pyrE, orotate phosphoribosyltransferase;
DCK, deoxycytidine kinase.
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Materials andMethods
BACTERIAL STRAINS, PLASMIDS, AND GROWTH MEDIA
E. coli SØ5218 (a gift from S. Eriksson, University of
Copenhagen) is a cdd-deficient strain expressing
the human DCK cDNA on the isopropyl -D-1-
thiogalactopyranoside (IPTG)-inducible pTrc99-A
plasmid (14). E. coli MG1655 (a gift from K.J. Jensen,
University of Copenhagen, Denmark) is a derivative of
the wild-type E. coli K-12 that requires pyrimidine in
minimal growth medium, due to suboptimal expres-
sion of the enzyme orotate phospho-ribosyltransferase
coded for by the orotate phosphoribosyltransferase
(pyrE) gene (16). Both strains were made self-
bioluminescent by transformation, using standard
methods previously described (9 ), with the broad-host
vector pBBR1MCS-2 (17) carrying the luxCDABE cas-
sette from Photorhabdus luminescens as an EcoRI PCR
fragment. All chemicals and growth media were sup-
plied by Sigma-Aldrich (www.sigmaaldrich. com) un-
less otherwise stated. Luria-Bertani growth medium
was used for routine culturing of bacteria. The antibi-
otics tetracycline, ampicillin, and kanamycin were
added at a final concentration of 10, 100, and 10 mg/L,
respectively. Growth inhibition experiments were per-
formed in Luria-Bertani growth medium, RPMI 1640
(Invitrogen, www.invitrogen.com), or AB minimal
medium (16) plus 2.0 g/L glucose and 2.0 g/L vitamin-
free casamino acids and supplemented with thiamine
and leucine at final concentrations of 1 and 20 mg/L,
respectively.
CELL LINES, BONE MARROW, AND BLOOD SAMPLES
The monocytic AML cell lines KG-1a and THP-1
(DSMZ, www.dsmz.de) were grown andmaintained as
a cell suspension in RPMI 1640medium supplemented
with 2 mmol/L glutamine (Invitrogen) and 10% fetal
calf serum (Biosera, www.biosera.com) at 37 °C and
5% CO2. Cultures were maintained at a density of
1–4 106 cells/mL and were monitored by vital stain-
ing using trypan blue. Cryopreserved bone marrow
samples, previously separated by density gradient cen-
trifugation to yield themononuclear cell fraction, were
thawed and resuspended inRPMI 1640mediumbefore
incubation with Ara-C. Mononuclear cells from fresh
AML peripheral blood samples (collected from pa-
tients at Frimley ParkHospital, Surrey, UK, and Bristol
Haematology and Oncology Centre, Bristol, UK, after
obtaining informed consent) were also isolated by den-
sity gradient centrifugation and resuspended in RPMI
1640medium. In all cases, samples were obtained from
patients at diagnosis, before the start of treatment, and
with blood blast burdens 80% and were analyzed
blind to avoid bias. Subsequent clinical outcome after
induction chemotherapy with Ara-C–containing
treatment cycles was available in all cases. Ara-C was
added at a final concentration of 25 mol/L, which
represents the equivalent of the standard in vivo dose of
200 mg  m2  day1 (based on an 80-kg individual
(see Table 1 in the Data Supplement that accompanies
the online version of this article at http://www.clinche-
m.org/content/vol56/issue12) (18).
CONSTRUCTION OF A cdd-DEFICIENT MUTANT OF E. coli MG1655
A library ofE. coliMG1655mutantswas constructed by
using random transposition mutagenesis with P1
phage carrying Tn10 transposon, which can transpose
from the phage into the E. coli chromosome, according
to Miller (19) with slight modification. Briefly, E. coli
MG1655 mutants were grown in Luria-Bertani broth
until the midexponential phase and were infected with
P1 phage at amultiplicity of infection of approximately
5. The infected cells were plated on Luria-Bertani agar
plates containing tetracycline to select for mutants car-
rying the transposon. The cddmutants were selected by
growth after 24-h incubation at 37 °C on plates contain-
ing 10 mg/L of the analog 5-fluoro-2deoxycytidine,
which is toxic to E. coli–containing cdd activity. The phe-
notype of the cddmutant (E. coliHA1) was confirmed by
the absence of cytidine deaminase activity.
WESTERN BLOT ANALYSIS FOR DCK EXPRESSION
Lyophilized HA1 cells were reconstituted with 1 mL
water per vial and incubated at 37 °C for 1 h. Cells were
diluted 1/10 in prewarmed RPMI 1640 containing tet-
racycline, ampicillin, and kanamycin, added at a final
concentration of 10, 100, and 10 mg/L, respectively. A
1-mL t 0 sample was removed, and 1 mmol/L IPTG
was added to the remaining culture. Cells were incu-
bated at 37 °C with shaking at 220 rpm. Samples of 1
mL were removed every 30 min for 3 h. The samples
collected at different time points were centrifuged, and
the supernatant was removed. Pellets were lysed with
100 L CelLyticB containing 2 mmol/L phenylmeth-
anesulfonyl fluoride and 10 mg/L DNase I, to extract
soluble protein. Protein concentrations were deter-
mined by Bradford Assay (A595 nm) using BSA as a
standard, and 100 ng protein for each sample was then
separated on a 12%SDS-PAGE gel for 1 h at 300V. The
separated proteins were transferred to a nitrocellulose
membrane for 1 h at 100 V. Membranes were blocked
for 1 h at room temperature with 3% BSA in Tris-
buffered saline with Tween. Detection of protein was
carried out by using the anti-dCK primary antibody
(rabbit polyclonal to dCK; Abcam AB38012, Abcam,
www.abcam.com) at 1:500 dilution and goat anti-
rabbit horse radish peroxidase–conjugated polyclonal
as secondary conjugate (Sigma A0545) at 1:5000 dilu-
tion. Presence of bound horse radish peroxidase con-
jugate was detected by using the BMchemiluminescent
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detection system (Roche, www.roche.com) and stan-
dard x-ray film (Kodak, www.kodak.co.uk).
BIOSENSOR DOSE RESPONSE ANALYSIS
An overnight culture of E. coliHA1 was diluted to an ab-
sorbance (A) at 600 nm (600 A) of 0.1 in RPMI 1640
medium and incubated for 30 min at 37 °C with shaking
at 220 rpm. Samples of 200 L with either Ara-C or flu-
darabine (F-ara-A) concentrations of 0–100mol/L and
1mmol/L IPTGwere loaded into a black-walledmicroti-
ter plate (Invitrogen). Bioluminescence and growth (600
A) weremonitored every 15min for 15 h in amultimode
microplate reader (Tecan, www. tecan.com).
CELL LYSIS ASSAY
Cell lines were harvested by centrifuging at 300g for
5 min at room temperature and resuspended in
Fig. 1. Biosensor response.
The effect of Ara-C concentrations (0.1, 1, 25, and 100
mol/L) on luminescence (A) and growth (B) of E. coli HA1 in
the presence of IPTG; the effect of IPTG induction of dCK in
the presence of Ara-C (C) is also shown. Growth was moni-
tored by measuring 600 A; luminescence is shown as relative
light units (RLU); n  10 and error bars represent SD.
Fig. 2. The effect of Ara-CTP on the biosensor.
Peak light emission, measured as relative light units (RLU),
from E. coli HA1 in RPMI at 37 °C treated with Ara-CTP at
12.5, 25, 50, 75, and 100 nmol/L (A) and 0, 25, 50, and 100
mol/L (B) in the absence and presence of AP (mean of
n 3 and error bars show range). (C), correlation between
Ara-CTP and light emission / AP (significance with
1-way ANOVA and Bonferroni adjusted post hoc tests,
shown in Table 3 in the online Data Supplement; ***P 
0.001). NS, not significant.
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RPMI 1640 with no additives at a concentration of
2  106 cells/mL. Cell lines, peripheral blood, and
bone marrow blasts were treated with 25 mol/L
Ara-C for 30 min at 37 °C and 5% CO2. After expo-
sure to Ara-C, cultures were centrifuged as previ-
ously described and the supernatant was removed.
Harvested cells were washed and resuspended in
fresh RPMI 1640 medium. EDTA and saponin were
added to cell suspensions at final concentrations of
1.5 mmol/L and 1.0 g/L, respectively. Samples were
vortex-mixed for 30 s, and cell debris was removed
bycentrifugationat 2800g for 5minat roomtemperature.
Lysate sampleswere eachmixedwithanovernight culture
of the reporter bacteria, freshly diluted to a 600A of 0.1 in
a blackmicrotiter plate (Invitrogen).
A total of 1 mmol/L IPTG and 10 U alkaline phos-
phatase (AP)was added to the relevant samples. Biolumi-
nescence and growth (600A) were monitored in a Tecan
multimodemicroplate reader. Ara-C toxicity was also as-
sayed with a 3-day cytotoxicity assay using the Cell Titer-
Glo® Luminescent Cell Viability Assay kit (Promega,
www.promega. com). Cells were treated as above with 25
mol/LAra-C for72hat37 °Cand5%CO2, toallowcells
to enter the S phase and hence be sensitized to Ara-CTP,
beforemeasuring intracellular levels of ATP according to
the manufacturer’s instructions (Promega G7570 Cell
Titer-Glo Luminescent Cell Viability Assay).
STATISTICAL ANALYSIS
Statistical significance was determined by using one-
way ANOVA with Bonferroni corrected post hoc tests
(GraphPad Prism 4). Number of repeat treatments was
3 or more throughout; standard deviation was calcu-
lated for n 10 repeats, and mean and range is shown
for n 3 repeats.
Results
E. coli SØ5218, the cdd-deficient strain constructed by
Wang et al. (15), expressing the human dCK gene, ex-
Fig. 3. IPTG induction of dCK expression in HA1 cells.
(A), Representative Western blot for time course of IPTG-induced expression of dCK protein between 0 and 3 h. (B), Effect of
IPTG-induced expression of dCK on light emission by HA1 with (treated) and without (control) 25 mol/L Ara-C (mean of n 
10 and error bars show SD). Expression is maximal at t  3 h.
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hibited reduced relative growth in the presence of
Ara-C in minimal medium but not in a rich growth
medium, due to incorporation of cytosine triphos-
phate instead of the toxic analog Ara-CTP into bacte-
rial DNA.
To measure Ara-C response in a nutrient-rich
intracellular environment, an alternative cdd-deficient
mutant of a bioluminescent E. coli MG1655 strain,
requiring exogenous pyrimidine due to subopti-
mal expression of the enzyme orotate phospho-
ribosyltransferase coded for by the pyrE gene (16), was
constructed by using transposon mutagenesis. This
mutant was further transformed with pTrcHUMdCK
(15) to give IPTG-inducible expression of dCK. The
newly constructed bacterial biosensor, E. coli HA1,
showed reduced growth in the presence of Ara-C, even
when assayed in nutrient-rich medium (Fig. 1B).
Ara-C caused significantly (P  0.001; see Table 2 in
the online Data Supplement) increased light output
from the biosensor (Fig. 1A) with concentrations as
low as 0.1 mol/L. This significantly increased light
output was only observed during treatment with the
pyrimidine analog Ara-C and only in the presence of
IPTG-activated dCK (Fig. 1C). The specificity of the
biosensor to Ara-Cwas indicated by a lack of biosensor
response in a control assay with the purine analog flu-
darabine (Fig. 1 in the online Data Supplement shows
that IPTG activation of dCK had no effect on E. coli
HA1 treated with fludarabine).
To increase the specificity of the assay, direct ef-
fects of the active intracellular drug derivative, Ara-
CTP, on the bacterial biosensor were monitored (Fig.
2). The results indicate that Ara-CTPdoes not enter the
reporter bacteria, showing no increase in light output
compared with the untreated control, unless AP is
added at the start of the assay. The increase in peak light
output in the AP-treated samples (Fig. 2, A and B) is
similar to that observed with Ara-C (Fig. 1A) and sup-
ports our reasoning. By measuring peak biolumines-
cence increase in the presence and absence of AP
(/), it is possible to quantify the intracellular conver-
sion of Ara-C toAra-CTP, within leukemic cells. Fig. 2, A
and C, show that there is good correlation between light
output / AP and nanomolar concentrations of Ara-
CTP and also that concentrations as low as 25 nmol/L
Fig. 4. Schematic of the cell lysis assay using E. coli HA1 to show intracellular response to Ara-C.
(A), Mononuclear cells from patients with AML incubated with Ara-C were washed and lysed in the presence of EDTA (1.5
mmol/L) and saponin (1.0 g/L). (B), Subsequent cell lysate (containing both Ara-C and Ara-CTP) was exposed to the bacterial
biosensor in the presence or absence of AP. (C), In the presence of AP, Ara-CTP is converted to Ara-C, which on entering the
bacterium allows the generation of bioluminescence. (D), In the absence of AP, Ara-CTP remains intact and cannot enter the
bacterium. (E), The ratio between / AP is directly proportional to the concentration of Ara-CTP in the patient blasts, which
is representative of the patient’s ability to convert Ara-C to Ara-CTP.
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can be detected by a significant increase in light output
(P 0.05; see Table 3 in the online Data Supplement).
A Western blot for IPTG-induced expression of
dCK in the biosensor showed a high level of expression
after 3 h (Fig. 3A), leading to the increase in biolumi-
nescence (Fig. 3B) only in Ara-C–treated cells plus
IPTG.
AML cell lines and leukemic cell samples from
AML patients with known clinical outcome to Ara-C
treatment were used to evaluate the assay outlined by
the schematic in Fig. 4. A 3-day cytotoxicity test con-
firmed that KG-1a cells were sensitive to Ara-C,
whereas the THP-1 cell line was partially resistant (Fig.
5F). Running the assay with and without AP in parallel
enabled the determination of the relative proportion of
Ara-C that had been converted within AML cells into
Ara-CTP. THP-1 cells that had not converted Ara-C
to Ara-CTP generated similar output whether or not
AP was present in the assay (Fig. 5, C and D). KG1-a
cells generated the greatest difference (P  0.001) in
light output, in the presence of AP, due to conversion
of Ara-C to Ara-CTP, indicating high drug response
(Fig. 5, A and B). The diagnostic discriminator, assum-
ing that generation of Ara-CTP in AML cells is the ma-
jor cause of cell death (4, 5 ), is the maximal difference
in light output between the IPTG (LI) and IPTG AP
(LIP) curves that are shown in Fig. 5E.
Data were analyzed by single point measurement
at peak light output, comparing treated and untreated
samples/ AP, as shown in Fig. 5E. The calculation
of the percentage response uses a simple formula:
Biosensor assay response (%)
 [(LIP/LI)25 mol/L  (LIP/LI)0 mol/L]  100
Preliminary assay of stored blood and bone marrow
samples taken at presentation from12 known respond-
ing and 12 known nonresponding Ara-C–treated pa-
Fig. 5. Effect of 30-min treatment with Ara-C (25 mol/L) on KG-1a (A and B) and THP-1 (C and D) cell lines by using
the bioluminescent bacterial reporter E. coli HA1.
Calculation of biosensor assay response is shown in (E). Equivalent results using the Cell Titer-Glo Luminescent Cell Viability
assay kit (survival index) are shown in (F). n  10, and error bars are SD.
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tients gave biosensor assay responses between 21 and
128% (median 55%) for responding patients and be-
tween 7 and 6% (median 0%) for nonresponding
patients (see Table 4 in the online Supplemental Data).
A typical example of each type is shown in Fig. 6; pa-
tient sample CR (with clinical outcome of complete
remission) showed a significant difference in the peak
light output (P 0.001) in the presence and absence of
AP, indicating response to a drug (Fig. 6A), whereas
sample NR (nonresponsive clinical outcome) exhib-
ited no significant difference (P 0.05) in light output
between the (/) curves, indicating a low concentra-
tion of Ara-CTP in the cells (Fig. 6B). The 3-day cyto-
toxicity test also showed that cells from patient
sample CR were significantly more sensitive to
Ara-C compared with cells from patient sample NR
(Fig. 6C).
Discussion
The cell lysis assay, using the bioluminescent bacterial
biosensor as a reporter of Ara-C activity, relies on the
response of bacteria to Ara-C. Because of the increased
metabolic rate and shorter cell cycle time of bacteria,
results can be achieved within a period of hours. In
contrast, mammalian cells undergo slower cell divi-
sion, which is the reason for the incubation times of 3
days or more needed to measure Ara-C cytotoxicity.
The increase in light output from the biosensor, which
closely correlates with the concentration of an active
drug under assay conditions in clinical samples, gives a
measure of mononuclear cell phenotype with regard to
intracellular Ara-CTP production during the time in-
terval that the cells are exposed to Ara-C.
The bioluminescence increase brought about by
Ara-C in the biosensor is similar to previous reports of
enhanced light emission in luciferase-based biosensors
brought about by impairment of the bacterial intracel-
lular equilibrium, leading to NADPH accumulation
(20), or byDNAdamage (21). It is reported that biolu-
minescence stimulatesDNA repair in bacteria, possibly
by providing photons for bacterial photolyase activity
(22) and that lux genes are regulated by the bacterial
SOS stress response (23), which may explain the in-
crease in bioluminescence in the presence of Ara-C.
The biosensor assay demonstrates Ara-C uptake
and activity in mononuclear cells isolated from AML
patient bone marrow and peripheral blood samples
within 8 h. The assay is the first of its kind, showing
phenotypic drug response within 8 h and here has been
used in a retrospective study of 24 clinical samples. This
is a preliminary validation study, and further work will
include prospective, controlled randomized trials to
establish the usefulness of the assay for AML and acute
lymphoblastic leukemia, which account for 2% of can-
cers in the UK (24). The assay has the potential to de-
tect response to Ara-C ofmyeloid blasts, irrespective of
whether they are obtained at diagnosis or at relapse/
nonresponse. This will be fully evaluated in prospective
clinical trials. The assay demonstrates that Ara-C sen-
sitivity of AML cells can be simply and accurately de-
termined within 8 h, by using the bioluminescent bac-
terial reporter construct. Currently, we are extending
our studies to include samples from a larger cohort of
AML patients to investigate correlation with clinical
outcome. If full clinical trials demonstrate that the as-
Fig. 6. Effect of 30 min treatment with Ara-C (25
mol/L) on clinical samples from 2 patients by use of
the bioluminescent bacterial reporter E. coli HA1.
Results from a clinically sensitive patient (A) and a clinically
resistant patient (B) are shown. Equivalent results using the
Cell Titer-Glo Luminescent Cell Viability assay kit (survival
index) are shown (C); significance was determined with
1-way ANOVA and Bonferroni adjusted post hoc tests.
***P  0.001. Mean of n  3 and error bars show range.
Bioluminescent Biosensor to Test Cytarabine Efficacy
Clinical Chemistry 56:12 (2010) 1869
say has predictive value, it may have the potential for
development as a diagnostic kit suitable for use in a
routine clinical laboratory, enabling rapid determina-
tion of the degree of response before patients undergo
chemotherapy.
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